MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy

Coverage is limited to molecular tests that aid diagnosis or exclusion of lung cancer for patients with an indeterminate pulmonary nodule after a non‑diagnostic bronchoscopy when the test will meaningfully inform management per consensus guidelines and alternate diagnostic methods are not feasible. The test and laboratory must meet test‑level requirements (peer‑reviewed clinical validity/utility, analytical validation, independent algorithm validation when applicable) and successfully complete a MolDX technical assessment; beneficiaries with prior same-assay testing, prior lung cancer, current cancer, or very low/high pretest risk are excluded.

"Beneficiary has undergone bronchoscopy for an indeterminate pulmonary nodule (IPN)."

Sign up to see full coverage criteria, indications, and limitations.